JPMorgan Chase & Co. reissued their neutral rating on shares of BTG (LON:BTG) in a research note published on Monday morning.

Several other equities research analysts also recently commented on the company. Numis Securities restated a buy rating and set a GBX 900 ($12.21) price objective on shares of BTG in a report on Friday, December 8th. Peel Hunt reiterated a hold rating and set a GBX 680 ($9.22) price target on shares of BTG in a report on Tuesday, November 14th. Finally, Deutsche Bank reiterated a buy rating and set a GBX 775 ($10.51) price target on shares of BTG in a report on Tuesday, November 7th. Two investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. BTG presently has an average rating of Buy and an average target price of GBX 771.63 ($10.46).

BTG (BTG) traded up GBX 0.50 ($0.01) during midday trading on Monday, hitting GBX 750.50 ($10.18). The stock had a trading volume of 602,924 shares, compared to its average volume of 453,385. The company has a market capitalization of $2,900.00 and a P/E ratio of 3,950.00. BTG has a 52-week low of GBX 528.36 ($7.17) and a 52-week high of GBX 784 ($10.63).

BTG (LON:BTG) last released its quarterly earnings data on Tuesday, November 14th. The company reported GBX 21 ($0.28) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of GBX 21 ($0.28). The firm had revenue of £341.30 million during the quarter. BTG had a return on equity of 10.80% and a net margin of 15.50%.

ILLEGAL ACTIVITY NOTICE: This story was first published by Daily Political and is owned by of Daily Political. If you are reading this story on another website, it was stolen and reposted in violation of US and international copyright and trademark legislation. The legal version of this story can be read at

About BTG

BTG plc is engaged in the business of healthcare, focusing on Interventional Medicine therapies for liver cancer, emphysema and vascular disorders, specialty pharmaceuticals for acute care uses, and a licensing business. The Company operates through three segments: Interventional Medicine, Specialty Pharmaceuticals and Licensing.

Analyst Recommendations for BTG (LON:BTG)

Receive News & Ratings for BTG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BTG and related companies with's FREE daily email newsletter.